vinorelbine


Also found in: Wikipedia.

vinorelbine

 [vi-nor´el-bēn]
a semisynthetic vinca alkaloid derived from vinblastine; administered intravenously as the tartrate salt as an antineoplastic agent in treatment of non–small cell lung cancer.

vinorelbine

/vi·nor·el·bine/ (vĭ-nor´el-bēn″) an antineoplasticvinca alkaloid used as the tartrate salt in the treatment of advanced non.

vinorelbine

Oncology An anticancer vinca alkaloid. See Vinblastine, Vincristine.

vinorelbine

A vinca alkaloid anticancer drug (see CYTOTOXIC DRUGS) used to treat lung and breast cancer. A brand name is Navelbine.
References in periodicals archive ?
Patients treated with LYNPARZA showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) compared with those who received chemotherapy (capecitabine, vinorelbine or eribulin).
After treated with vinorelbine and/or gemcitabine as second- or third-line therapy, 46% of patients had stable disease.
Finalizado esse ciclo, iniciou-se o protocolo Gencitabina + Vinorelbine, ambos administrados por via endovenosa.
Vinorelbine tartrate injection was intravenously infused on the 1st and 8th days at the dose of 20-25 mg/m2, and cisplatin was intravenously infused on the 1st to 3rd days at the dose of 20-30 mg/m2.
It can also be treated with platinum-based drugs, and drugs such as capecitabine, eribulin, gemcitabine, ixabepilone, and vinorelbine.
The alternatives assessed here were (L+C) compared to trastuzumab + capecitabine (T+C), trastuzumab + paclitaxel (T+P), trastuzumab + docetaxel (T+D), and trastuzumab + vinorelbine (T+V).
The effect of oral vinorelbine as maintenance therapy was investigated in a phase II multicenter clinical trial.
Platinum-based chemotherapy is used for some cases, as well as vinorelbine, paclitaxel, gemcitabine and etoposid, which are rarely used in combination.
Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies.
Cisplatin and Vinorelbine adjuvant chemotherapy was administered with no overt complications; however recurrence of the disease was discovered radiologically one year post-operatively in the form of a left hilar soft tissue mass with bony metastases.
The other example of CMA could be found in the study by the Southwest Oncology Group in which they compared the use of vinorelbine plus cisplatin versus paclitaxel plus carboplatin in the treatment of advanced NSCLC found no statistically significant difference in survival rate or quality of life between the treatment arms.